Leqembi®

Understanding Leqembi® 

Leqembi® (lecanemab-irmb) is an FDA-approved monoclonal antibody treatment for early Alzheimer’s disease. It is designed to slow disease progression by reducing the buildup of amyloid-beta plaques in the brain, which are believed to play a key role in the development and progression of Alzheimer’s.

How Leqembi® Works:

• Targets and clears amyloid-beta plaques in the brain
• Slows cognitive decline in early-stage Alzheimer’s disease
• May help preserve memory and cognitive function longer

FDA Approval:

• Accelerated Approval: January 6, 2023
• Traditional (Full) Approval: July 6, 2023

For more information, please visit the Leqembi® patient website and speak with your healthcare provider to determine if Leqembi® is the right treatment option for you.